A Geneva hydrogel keeps insulin cells alive on the road to a bioartificial pancreas
A translucent 9 mm hydrogel implant acting as a living bioartificial pancreas, glowing with pancreatic islet clusters and new microvessels inside a clinical research frame.📷 AI-generated image / TECH&SPACE
- ★Amniogel creates a protective environment for pancreatic islets and vessel-forming cells.
- ★In diabetic mice, the graft regulated glucose for up to 100 days.
- ★The next step is producing larger grafts required for potential human therapy.
Type 1 diabetes is a precise and punishing failure mode: the immune system destroys pancreatic beta cells, leaving the patient dependent on glucose monitoring and insulin delivery. That is why the Geneva result matters, but it should be read with discipline. Researchers from the University of Geneva and Geneva University Hospitals developed Amniogel, a soft protective hydrogel designed to support transplanted insulin-producing cells inside the body.
According to the report carried by MedicalXpress, the team regulated blood sugar in diabetic mice by embedding pancreatic islets together with vessel-forming cells inside the hydrogel. That detail is not decorative. Insulin-producing cells do not simply need to be placed in the body; they need oxygen, nutrients and fast integration with the host. Without that vascular support, transplantation can look elegant in concept and fail at the biological interface.
A UNIGE and HUG team showed that a hydrogel carrying pancreatic islets and vessel-forming cells can regulate glucose in diabetic mice.
Close biological cross-section of pancreatic islets suspended in Amniogel while capillary-like vessels grow through the matrix toward them.📷 AI-generated image / TECH&SPACE
Amniogel is therefore not just a “diabetes gel.” It is a controlled microenvironment for a graft. The supplied research brief describes a natural-like protective setting in which pancreatic islets are combined with cells that can help form blood vessels. The experiment points to 9 mm grafts and blood-glucose regulation for 100 days. In a mouse model, that is a meaningful functional signal, but it is not yet evidence of a clinic-ready therapy.
The results are published in Trends in Biotechnology, and the broader target is a bioartificial pancreas rather than a one-off transplant material. The concept is straightforward: instead of replacing insulin from the outside every day, implant a living system that can sense glucose and respond to it. If such a system becomes reliable, it could shift type 1 diabetes care away from constant correction and toward longer-term biological regulation.
The hard problems are still the hard problems. Islet transplantation has long faced donor shortages, immune rejection and poor survival of cells after implantation. A hydrogel can help with protection and vascularization, but a human therapy would require much larger cell volumes, tighter immune control and evidence that the implant keeps functioning when the work moves beyond a controlled mouse model.
That makes the next step the most important part of the story: producing larger grafts suitable for human requirements. If Amniogel can preserve structure, oxygen supply and insulin response at that scale, it could become a serious component of a bioartificial pancreas. If it cannot, it will still stand as useful experimental evidence that the field may need smarter cell environments, not only better pumps, sensors or dosing algorithms.
